Among its identified metabolites, Cryptotanshinone demonstrated strong binding affinity and structural stability toward multiple cancer-associated protein targets, showing binding efficacy comparable to the clinically approved EGFR inhibitor Erlotinib. The gene discussed is EGFR; the disease is cancer.